Paula Greter: Access and Innovation in Hemophilia through ERAH2026
Paula Greter, Commercial Strategy and Market Access Director at Roche Brazil, shared a post on LinkedIn:
”Participating in ERAH2026 truly reinforced what drives me at Roche Farma Brasil: our purpose to transform science into hope and meaningful quality of life for families.
This is an unyielding pursuit of solutions that challenge the impossible.
In our long-term journey with the community, hemophilia remains a core priority, keeping us dedicated to securing two essential pillars: access and innovation.
To drive the future forward , we continually invest in developing next-generation approaches.
Alongside this, we take great pride in our humanitarian aid program in partnership with the WFH, bringing access to communities in over 30 countries.
Our commitment is continuous: ensuring that these patients’ lives keep moving forward, always.
Let’s keep this momentum alive.”
Stay updated with Hemostasis Today.
-
Jul 13, 2026, 11:25Luisa Müller: Advancing Anticoagulation Strategies for VITT at ISTH 2026
-
Jul 13, 2026, 10:49Joshua Zeidner: Advancing Menin Inhibitor Therapy in MD Education AML-ALL US Focus 2026
-
Jul 13, 2026, 10:25Flora Peyvandi: A Practical Approach to ALT Elevation After Gene Therapy at ISTH 2026
-
Jul 13, 2026, 10:02Jessica Garcia: Where Science and Community Come Together at ISTH 2026
-
Jul 13, 2026, 09:46Fabrice Cognasse: Is There Such a Thing as the Perfect Platelet Product?
-
Jul 13, 2026, 09:42Cancer-Associated Arterial Thromboembolism: Redefining the Thrombotic Burden in Oncology
-
Jul 13, 2026, 05:59Connecting and Collaborating at ISTH 2026 – NNHF
-
Jul 13, 2026, 05:58Lara Monica: Back at ISTH – Looking Forward to Science and Reconnections!
-
Jul 13, 2026, 05:57Barbara Adams Krolak: Exciting Updates From the ISTH 2026 Regulatory Session